在澳大利亚OPAL数据集中的类风湿性关节炎患者中,第一线巴里西提尼布的比较有效性
Sabina Ciciriello1, Geoffrey Littlejohn2, Tamas Treuer3
1OPAL Rheumatology Ltd, Sydney, New South Wales, Australia, and The Royal Melbourne Hospital Melbourne, Victoria, Australia.
ACR open rheumatology
|June 12, 2023
概括
在类风湿性关节炎患者中,一线巴里西替尼 (BARI) 治疗持续时间比瘤亡因子抑制剂 (TNFi) 长达24个月. 然而,与组合疗法相比,BARI单一疗法在持久性方面没有显著差异.
科学领域:
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 类风湿性关节炎 (RA) 管理包括选择适当的第一线生物或向合成疾病修饰性抗风湿药物 (DMARDs).
- 治疗持续性是长期控制RA疾病和患者结果的关键因素.
- 关于巴里西提尼布 (BARI) 与瘤亡因子抑制剂 (TNFi) 作为一线治疗的持久性的比较数据对于临床决策很重要.
研究的目的:
- 在类风湿性关节炎 (RA) 患者中,比较一线巴里西提尼 (BARI) 与一线瘤亡因子抑制剂 (TNFi) 的治疗持久性.
- 评估BARI在单一治疗开始时与常规合成DMARDs (csDMARDs) 结合使用的持续性.
主要方法:
- 在2015年10月至2021年9月期间使用OPAL数据集对RA患者进行一线BARI或TNFi的回顾性分析.
- 6,12和24个月的药物存活时间使用受限平均存活时间 (RMST) 进行评估.
- 使用先进的统计方法,包括多重归算和治疗权重的逆概率,以处理缺失的数据和混.
主要成果:
- 在6个月或12个月后,在BARI和TNFi之间没有观察到药物存活的显著差异.
- 与24个月的TNFi相比,一线BARI显示药物存活时间明显更长 (差异为1.00个月).
- 6,12或24个月后,在BARI单疗和BARI组合疗法之间没有发现药物存活率的显著差异.
结论:
- 虽然一线BARI在统计学上比TNFi持续时间长达24个月,但1.00个月的差异不被认为具有临床意义.
- 对BARI的治疗持久性没有显著差异,无论是作为单疗法开始还是与csDMARDs结合使用.
相关概念视频
The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K
Genome-wide Association Studies-GWAS
13.6K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.6K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
177
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
177
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
202
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
202
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
161
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
161
Rheumatic Heart Disease III: Medical Management
22
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
22


